Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia

Depression and Anxiety
Siegfried Kasper

Abstract

This analysis of data from the open-label extension (OLE) phases of three randomized clinical trials of quetiapine in patients with schizophrenia (n=415) was undertaken to investigate whether the initial improvements in anxiety and depressive symptoms were maintained during long-term treatment. The mean (95% confidence interval [CI]) change from the acute phase baseline in the Factor I score of the Brief Psychiatric Rating Scale (BPRS), which includes somatic concern, anxiety, guilt feelings, and depression, was calculated at the OLE baseline and at various time points up to 156 weeks. After 6 weeks of treatment with quetiapine during the acute phase, the mean (95% CI) change in the BPRS Factor I score was -1.13 (-1.23, -1.04) and after 156 weeks, it was -1.33 (-1.78, -0.87). Therefore, the efficacy of quetiapine for the treatment of anxiety and depressive symptoms is maintained in long-term treatment.

References

Jan 1, 1979·Current Medical Research and Opinion·M G Budden
May 1, 1996·The British Journal of Psychiatry. Supplement·S R HirschL A Arvanitis
Mar 18, 2000·Psychological Medicine·S PriebeW Kaiser
Mar 17, 2001·International Clinical Psychopharmacology·J Kane
Aug 24, 2001·Schizophrenia Research·J D HuppertT E Smith
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·D Naber, A Karow
Jan 1, 2003·International Journal of Psychiatry in Clinical Practice·A De NayerCa Altman

❮ Previous
Next ❯

Citations

Apr 1, 2007·Neuropsychiatric Disease and Treatment·Michael RiedelHans-Jürgen Möller
Jan 1, 2008·International Journal of Psychiatry in Clinical Practice·Stanley Victor CattsJames Scott
Mar 31, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Feb 25, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nienke C C VulinkDamiaan Denys
Aug 19, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sandeep VaishnaviJonathan R T Davidson
Jul 17, 2009·Human Psychopharmacology·Kyoung-Uk LeeTae-Youn Jun
Sep 12, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·A KonstantinidisS Kasper
Jun 24, 2006·Drug Discovery Today·Kurt Rasmussen
Oct 12, 2016·International Journal of Molecular Sciences·Maurizio PompiliPaolo Girardi
Mar 7, 2013·CNS Spectrums·Debbi A Morrissette, Stephen M Stahl
Jul 6, 2007·Expert Review of Neurotherapeutics·Donald L Rowe
Oct 19, 2006·Journal of Psychopharmacology·Simon Burton
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Joseph PeuskensEduard Vieta
Dec 20, 2007·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Adib EssaliJohn Rathbone
Oct 21, 2015·CNS Drugs·Henk Temmingh, Dan J Stein
Jun 21, 2005·Clinical Neuropharmacology·Joseph MerguiVladimir Lerner
Sep 16, 2013·The Medical Journal of Australia·Peter Bosanac, David J Castle

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.